RENOVA 0.05% Rx
Generic Name and Formulations:
Tretinoin 0.05%; crm.
Valeant Pharmaceuticals, Inc
Indications for RENOVA 0.05%:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
≥18 years: Wash face with mild soap, pat dry and wait 20–30 minutes before use. Apply a small amount to cover entire affected area lightly once daily in the PM. Do not wash face, or use other skin care products for at least 1 hour after application. Discontinue if sensitivity, irritation, or systemic reactions occur.
<18yrs: not recommended.
Do not use on sunburn, eczema, other chronic skin conditions, or for sun-sensitive patients. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid photosensitizers, topical irritants, and drying agents.
Local erythema, peeling, dry skin, burning, stinging, pruritus, hypo- or hyperpigmentation.
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit